We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Lonodelestat

News List

Santhera, Cold Spring Harbor Lab to Investigate Lonodelestat in COVID-19-related ARDS americanpharmaceuticalreview
April 30, 2020
Santhera Pharmaceuticals has entered into a collaboration agreement with Cold Spring Harbor Laboratory (CSHL) to investigate the potential of lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase (hNE).
Santhera explores lonodelestat to treat ARDS in Covid-19 patients pharmaceutical-technology
April 30, 2020
Swiss-based Santhera Pharmaceuticals has partnered with Cold Spring Harbor Laboratory (CSHL) to explore the use of lonodelestat (POL6014) as a potential treatment for acute respiratory distress syndrome (ARDS) caused by Covid-19.
Santhera, CSHL to Investigate Lonodelestat in COVID-19-related ARDS contractpharma
April 28, 2020
Lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase (hNE), has potential as a therapeutic intervention for COVID-19-related ARDS.